FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2589570626> ?p ?o ?g. }

• W2589570626 endingPage "104" @default.
• W2589570626 startingPage "104" @default.
• W2589570626 abstract "104 Background: The 21-gene recurrence score (RS) assay (OncotypeDX) is prognostic in stage I-II, ER+, HER2-, node negative breast cancer (BC). While RS reflects tumor gene expression its interaction with host factors including metabolic syndrome (MS) is unclear. MS conditions such as obesity have been associated with increased risk of BC and worse prognosis. The aim of this study is to determine correlations between MS conditions and RS group or BC outcomes in both pre- and post-menopausal women. Methods: We retrospectively reviewed women with stage I-II, ER+, HER2- node negative BC evaluated with RS assay treated at University of Michigan since 2005. Demographic, pathologic and treatment data, MS criteria and menopausal status were abstracted from medical records. MS was defined as ≥ 3 of the following within 6 months of diagnosis: BMI ≥ 27.7kg/m 2 ; hypertension (HTN); impaired fasting glucose (IFG); HDL < 50mg/dL; hypertriglyceridemia (trig). RS groups were defined as low ( < 18), intermediate (18-30) and high ( > 31). Results: Of 533 eligible women 74% had stage I disease and 61% were postmenopausal at diagnosis. MS criteria prevalence was 43% BMI, 42% HTN, 34% trig, 14% IFG and 13% HDL. MS was present in 22% and more common in post- vs pre-menopausal women (30% vs 9%; p < 0.0001). RS groups were 55% low, 38% intermediate and 7% high. There was no significant association between RS group and overall MS status or any individual criterion, controlling for stage, and no association after stratification by menopausal status. Postmenopausal status was associated with higher RS group (p = 0.039), independent of stage. Over the 4.2 year median follow-up there were 7 deaths and 20 events, including 5 DCIS, 3 local and 11 distant recurrences and 1 second primary BC. There was insufficient power to detect associations between event rate and MS status. Conclusions: MS and comprising conditions are present in many early stage breast cancer patients, especially postmenopausal women. We were unable to identify associations between RS group and MS criteria. Thus the known worse BC prognosis with MS is not reflected in the RS. Identification of factors underlying this higher risk will be important for optimizing management of patients with breast cancer and MS." @default.
• W2589570626 created "2017-03-03" @default.
• W2589570626 creator A5062446153 @default.
• W2589570626 creator A5063192858 @default.
• W2589570626 creator A5066663190 @default.
• W2589570626 date "2015-10-01" @default.
• W2589570626 modified "2023-10-18" @default.
• W2589570626 title "Metabolic syndrome and breast cancer recurrence within the 21-gene recurrence score assay." @default.
• W2589570626 doi "https://doi.org/10.1200/jco.2015.33.28_suppl.104" @default.
• W2589570626 hasPublicationYear "2015" @default.
• W2589570626 type Work @default.
• W2589570626 sameAs 2589570626 @default.
• W2589570626 citedByCount "0" @default.
• W2589570626 crossrefType "journal-article" @default.
• W2589570626 hasAuthorship W2589570626A5062446153 @default.
• W2589570626 hasAuthorship W2589570626A5063192858 @default.
• W2589570626 hasAuthorship W2589570626A5066663190 @default.
• W2589570626 hasConcept C121608353 @default.
• W2589570626 hasConcept C126322002 @default.
• W2589570626 hasConcept C143998085 @default.
• W2589570626 hasConcept C146357865 @default.
• W2589570626 hasConcept C151730666 @default.
• W2589570626 hasConcept C2776919658 @default.
• W2589570626 hasConcept C2778163477 @default.
• W2589570626 hasConcept C2778913445 @default.
• W2589570626 hasConcept C2780221984 @default.
• W2589570626 hasConcept C2780578515 @default.
• W2589570626 hasConcept C29456083 @default.
• W2589570626 hasConcept C511355011 @default.
• W2589570626 hasConcept C530470458 @default.
• W2589570626 hasConcept C71924100 @default.
• W2589570626 hasConcept C86803240 @default.
• W2589570626 hasConcept C90924648 @default.
• W2589570626 hasConceptScore W2589570626C121608353 @default.
• W2589570626 hasConceptScore W2589570626C126322002 @default.
• W2589570626 hasConceptScore W2589570626C143998085 @default.
• W2589570626 hasConceptScore W2589570626C146357865 @default.
• W2589570626 hasConceptScore W2589570626C151730666 @default.
• W2589570626 hasConceptScore W2589570626C2776919658 @default.
• W2589570626 hasConceptScore W2589570626C2778163477 @default.
• W2589570626 hasConceptScore W2589570626C2778913445 @default.
• W2589570626 hasConceptScore W2589570626C2780221984 @default.
• W2589570626 hasConceptScore W2589570626C2780578515 @default.
• W2589570626 hasConceptScore W2589570626C29456083 @default.
• W2589570626 hasConceptScore W2589570626C511355011 @default.
• W2589570626 hasConceptScore W2589570626C530470458 @default.
• W2589570626 hasConceptScore W2589570626C71924100 @default.
• W2589570626 hasConceptScore W2589570626C86803240 @default.
• W2589570626 hasConceptScore W2589570626C90924648 @default.
• W2589570626 hasIssue "28_suppl" @default.
• W2589570626 hasLocation W25895706261 @default.
• W2589570626 hasOpenAccess W2589570626 @default.
• W2589570626 hasPrimaryLocation W25895706261 @default.
• W2589570626 hasRelatedWork W1516729834 @default.
• W2589570626 hasRelatedWork W1998545432 @default.
• W2589570626 hasRelatedWork W2066964288 @default.
• W2589570626 hasRelatedWork W2136321264 @default.
• W2589570626 hasRelatedWork W2171538978 @default.
• W2589570626 hasRelatedWork W2373456992 @default.
• W2589570626 hasRelatedWork W2524205622 @default.
• W2589570626 hasRelatedWork W2561118033 @default.
• W2589570626 hasRelatedWork W3198345099 @default.
• W2589570626 hasRelatedWork W2406682690 @default.
• W2589570626 hasVolume "33" @default.
• W2589570626 isParatext "false" @default.
• W2589570626 isRetracted "false" @default.
• W2589570626 magId "2589570626" @default.
• W2589570626 workType "article" @default.